Update information
February 2016: Sections 4.41 and 4.42 have been updated with the incremental cost-effectiveness ratios (ICERs) including the patient access scheme.
Contact details for Merck, Sharp & Dohme and UCB Pharma have been added to section 5.4.
ISBN: 978-1-4731-1655-9